NVision Raises $55 Million to Expand Into Quantum Computing as Total Funding Reaches $120 Million
Updated
Updated · CTech · May 13
NVision Raises $55 Million to Expand Into Quantum Computing as Total Funding Reaches $120 Million
2 articles · Updated · CTech · May 13
$55 million in Series B funding will finance NVision’s move beyond quantum MRI into quantum computing, with Abbott leading the round and a $17 million European Investment Bank venture loan included.
The expansion builds on NVision’s discovery of organic molecule-based qubits, which it is integrating into photonic chips through its PIQC platform designed to work with standard semiconductor manufacturing.
POLARIS remains the company’s near-term commercial base: the quantum sensing system boosts MRI signals to track metabolism in real time, and about 20 systems are expected across the U.S., Europe and Asia by year-end.
NVision says the longer-term goal is to link quantum computing and quantum sensing in drug development, using quantum systems to design candidates and POLARIS to quickly validate their behavior in living biology.
Abbott joined as NVision’s sole strategic diagnostics investor, giving it a route to explore quantum applications in disease detection, monitoring and clinical decision-making.
Can one company truly master both quantum computing and medical imaging to revolutionize drug discovery?
Will quantum-enhanced MRI reveal disease secrets fast enough to justify a $120 million investment?
NVision Secures $55 Million Series B to Expand Quantum Healthcare Platform Globally
Overview
NVision, founded in 2015 in Ulm, Germany by a team of quantum experts, has leveraged the region’s strengths in quantum optics and microelectronics to pioneer parahydrogen-induced polarization (PHIP) technology. This innovation became the foundation for their POLARIS quantum-enhanced MRI platform. Early support from the German government and a successful Series A funding round enabled NVision to advance its technology and form key partnerships, such as with Siemens Healthineers. These strategic moves have positioned NVision at the forefront of integrating quantum sensing and computing to accelerate drug discovery and transform healthcare diagnostics.